Q4: For people with dementia with associated depression, do antidepressants when compared to placebo/comparator produce benefits/harm in the specified outcomes?
Q2: For people with dementia, does memantine, when compared to placebo/comparator, produce benefits/harm in the specified outcomes in non-specialist health settings?
From raising awareness to building capacity
Meeting Report
World Health Organization, Geneva, Switzerland 16 -18 September 2013
Responses to epidemics, emergencies and disasters raise many ethical issues for the people involved, including public health specialists and policy makers. This training manual provides material on ethical issues in research, surveillance and patient care in these difficult contexts.
A collaborative project of World Health Organization and
Lifting The Burden
Scoping Question: For adults and children living with HIV, which antiepileptic medications (such as phenobarbital, phenytoin, carbamazepine or valproic acid) produce benefits and/or harms when compared to a placebo or controls?
Psychoactive substance use affects the functioning of the brain and leads to impaired driving
Aktuelle Themen und perspektiven für eine gesundheitsfördernde stadtentwicklungWeltweit nimmt die Urbanisierung zu: Inzwischen lebt mehr als die Hälfte der Weltbevölkerung in Städten, in Europa sind es deutlich mehr als 70% der Bevölkerung (WHO, 2010a). Aufgrund die...ser Entwicklung hat sich »Urban Health« als neues Forschungsfeld etabliert, in dem der Einfluss der städtischen Umwelt auf die Gesundheit unter-sucht wird (Vlahov & Galea, 2003; Galea & Vlahov, 2005a; Heaton et al., 2010; Braür & Hystad, 2014).
more
Children's Health and the Environment WHO Training Package for the Health Sector World Health Organization
A tool for measuring alcohol policy implementation
(New 2015)
Scoping question: In school students aged 14-‐‑15 years, are school-‐‑based interventions effective in reducing deaths from suicide and suicide attempts compared to care-‐‑as-‐‑usual?
Q3: For behavioural and psychological symptoms in people with dementia, do following drugs, when compared to placebo/comparator, produce benefits/harm in the specified outcomes?